Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.

Author Information (click to view)

Liepelt A, Tacke F,

Liepelt A, Tacke F, (click to view)

Liepelt A, Tacke F,

Share on FacebookTweet about this on TwitterShare on LinkedIn

American journal of physiology. Gastrointestinal and liver physiology 2016 6 16() ajpgi.00193.2016 doi 10.1152/ajpgi.00193.2016


The chemokine Stromal cell-Derived Factor-1 (SDF-1) or CXCL12 is constitutively expressed in healthy liver. However, its expression increases following acute or chronic liver injury. Liver sinusoidal endothelial cells (LSEC), hepatic stellate cells (HSC) and malignant hepatocytes are important sources of SDF-1/CXCL12 in liver diseases. CXCL12 is able to activate two chemokine receptors with different downstream signaling pathways, CXCR4 and CXCR7. CXCR7 expression is relevant on LSEC, while HSC, mesenchymal stem cells and tumor cells mainly respond via CXCR4. Here, we summarize recent developments in the field of liver diseases involving this chemokine and its receptors. SDF-1 dependent signaling contributes to modulating acute liver injury and subsequent tissue regeneration. By activating HSC and recruiting mesenchymal cells from bone marrow, CXCL12 can promote liver fibrosis progression, while CXCL12-CXCR7 interactions endorse pro-regenerative responses in chronic injury. Moreover, the SDF-1 pathway is linked to development of hepatocellular carcinoma (HCC) by promoting tumor growth, angiogenesis, and HCC metastasis. High hepatic CXCR4 expression has been suggested as a biomarker indicating poor prognosis of HCC patients. Tumor-infiltrating myeloid derived suppressor cells (MDSC) also express CXCR4 and migrate towards CXCL12. Thus, CXCL12 inhibition might not only directly block HCC growth but modulate the tumor microenvironment (angiogenesis, MDSC), thereby sensitizing HCC patients to conventional or emerging novel cancer therapies (e.g., sorafenib, regorafenib, nivolumab, pembrolizumab). We herein summarize the current knowledge on the complex interplay between CXCL12 and CXCR4/CXCR7 in liver diseases and discuss approaches on the therapeutic targeting of these axes in hepatitis, fibrosis and liver cancer.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × five =